Compare UVV & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | SPTX |
|---|---|---|
| Founded | 1886 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1994 | 2026 |
| Metric | UVV | SPTX |
|---|---|---|
| Price | $45.62 | $24.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 302.5K | 106.4K |
| Earning Date | 05-28-2026 | N/A |
| Dividend Yield | ★ 6.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,885,078,000.00 | N/A |
| Revenue This Year | $0.67 | N/A |
| Revenue Next Year | $0.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $43.36 | $17.59 |
| 52 Week High | $59.38 | $26.32 |
| Indicator | UVV | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 64.32 |
| Support Level | $43.36 | $18.72 |
| Resistance Level | $54.26 | N/A |
| Average True Range (ATR) | 1.45 | 1.54 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 20.38 | 57.03 |
Universal Corp is an international leaf tobacco supplier. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Tobacco Operations segment involves procuring and processing flue-cured, burley, dark air-cured, and oriental leaf tobacco for manufacturers of consumer tobacco products and performing related services. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, the Philippines, Germany, and Other Countries, with the majority of revenue from the USA.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.